Interobserver variability in HER-2/neu reporting on immunohistochemistry in breast carcinomas. 2014

Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad

OBJECTIVE To evaluate human epidermal growth factor receptor 2 (HER2/neu) interobserver variability between specially trained and untrained general histopathologists. METHODS The retrospective study cases of invasive breast carcinoma received at Shifa International Hospital, Islamabad, from June 2010 to December 2011, for assessment of HER2/neu status by immunohistochemistry which were retrieved from the files and, 30 consecutive cases each of score 0, 1+, 2+ and 3+ were selected for a total of 120 cases. Two groups of two histopathologists each examined the cases blindly. One group had attended a short course in Germany, while the other group comprised two qualified histopathologists who had not had any special training. Each histopathologist reported the cases independently according to standard guidelines. Kappa statistics were applied. RESULTS The trained group of histopathologists showed agreement in 113 (94%) cases. Kappa value was calculated to be 0.96 which means 'perfect agreement. In contrast the untrained group showed agreement in 83 (69%) cases with a kappa value of 0.59 which means 'moderate agreement. CONCLUSIONS Interobserver variability in immunohistochemical scoring of HER-2/neu in breast carcinoma is high among untrained general histopathologists. This may adversely affect the selection of patients with cancers who could benefit from Herceptin therapy.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics

Related Publications

Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
August 2003, The Journal of molecular diagnostics : JMD,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
November 2001, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
June 2000, American journal of clinical pathology,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
January 2014, Indian journal of pathology & microbiology,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
June 2004, Analytical and quantitative cytology and histology,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
July 2002, Breast cancer research and treatment,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
March 2003, Diagnostic cytopathology,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
January 2011, Asian Pacific journal of cancer prevention : APJCP,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
October 2003, American journal of clinical oncology,
Nadira Mamoon, and Fareeha Naseer Syed, and Sajid Mushtaq, and Humaira Nasir, and Imran Nazir Ahmad
June 2008, Journal of digital imaging,
Copied contents to your clipboard!